Compare Capri Holdings Ltd (CPRI) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Gilead Sciences, Inc. — how do they compare? Capri Holdings Ltd trades at $15.34 (market cap $1.75B), while Gilead Sciences, Inc. trades at $136.9 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 96.2× Capri Holdings Ltd's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals.
| CPRI | GILD | |
|---|---|---|
Market Cap | $1.75B | $168.35B |
Sector | Consumer Staples | Health |
52-Week High | $27.66 | $155.80 |
52-Week Low | $14.98 | $110.56 |
Enterprise Value | $3.03B | $191.42B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $15.43, down 65% over five years but showing recent earnings momentum with three consecutive quarterly beats. The stock faces bearish technical signals with moving averages indicating downward pressure, while fundamentals reveal declining revenue from $5.7B in 2022 to $4.4B in 2025 and a significant net loss of -$1.18B. Analyst consensus sits at $19.60 with mixed ratings (44% Buy, 52% Hold), reflecting cautious optimism about the company's turnaround strategy post-Versace sale.
The investment case hinges on CPRI's ability to stabilize Michael Kors and grow Jimmy Choo profitability, but risks include ongoing revenue declines, luxury market softness, and high debt levels. With the current price near 52-week lows and 27% upside to consensus target, the stock offers potential for recovery if management executes its revamp plans successfully, though macroeconomic headwinds and brand challenges remain significant concerns.
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
